Clinical Trials
Clinical trials are a necessary part of the process of developing new approaches to treating retinal conditions and help us understand retinal diseases more thoroughly. The specific trials we are conducting change regularly, but are all focused on optimizing outcomes for patients with retinal diseases. There are many potential benefits to participating in a clinical trial, including helping to advance the field of retinal diseases which include the most common causes of blindness in the USA and most developed countries around the world. Each clinical study has specific criteria that participants must meet. If you’re interested in participating in a clinical trial, please ask your doctor.
Wet Age-Related Macular Degeneration
A Double-Masked, Randomized, Multicenter, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of MT-0814 for the Treatment of Patients with Age Related Macular Degeneration
A Multicenter, Randomized, Double-masked Phase IIIa Study to Assess Safety and Efficacy of Brolucizumab 6 mg Q4 Weeks Compared to Aflibercept 2 mg Q4 Weeks in Patients with Neovascular Age-Related Macular Degeneration (nAMD) with Persistent Retinal Fluid
A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-related Macular Degeneration
A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-2)
A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane versus Lucentis® in Patients with Neovascular Age-Related Macular Degeneration
A Clinical effectiveness, multicenter, randomized, double-masked, controlled study of the efficacy and safety of ONS-5010 in subjects with subfoveal choroidal neovascularization (CNV) secondary to Age-Related Macular Degeneration (AMD)
NCT not yet available – A Multi-Center, Non-Randomized, Open-Label, Administration in Patients with Neovascular Age-Related Macular Degeneration
A Phase 2, Prospective, Randomized, Double-masked, Active Comparator controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects with Neovascular (Wet) Age-related Macular Degeneration
A Phase 2b Multicenter Dose-Ranging Study Evaluating the Safety and Efficacy of a Long-acting Intravitreal Sunitinib Malate Depot Formulation (GB-102) Compared to Intravitreal Aflibercept in Subjects with Neovascular (Wet) Age-related Macular Degeneration
Dry Age-related Macular Degeneration
A Phase III, Multi-Center, Randomized, Double-Masked, Sham Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
A Phase III, Multi-Center, Randomized, Double-Masked, Sham Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
A Genetic Screening and Registry Study to Evaluate Long-term Clinical Outcomes and Disease Progression in Subjects with Non-Central Geographic Atrophy (GA) Who Are Carriers of High-Risk Genetic Complement Variants Associated with Dry Age-related Macular Degeneration (AMD)
A Prospective Natural History Study to Evaluate Clinical Characteristics and Disease Progression in Subjects with Non-Central Geographic Atrophy (GA) Who Are Carriers of High-Risk Genetic Variants of Complement Factor H (CFH)
Longitudinal Observational Study of Non Exudative Age-Related Macular Degeneration Imaged with Swept Source Optical Coherence Tomography
A Phase II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Study of the Safety, Tolerability, and Evidence of Activity of Intravitreal Injection of RO7171009 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase 2, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects with Age-Related Macular Degeneration with Geographic Atrophy (ReCLAIM-2)
A Phase 1, Multicenter, Open-Label, Single-Dose and Multiple-Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravitreal Injections of NGM621 in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
A Phase II, randomized, Placebo-controlled, Double-Masked, Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-LRX, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration
Safety, tolerability and pharmacokinetics of single rising intravitreal doses of BI 754132 in patients with geographic atrophy secondary to age-related macular degeneration (open label, non-randomized, uncontrolled)
Diabetic Macular Edema
A Phase Ib/IIa Study of OPT-302 in Combination with Aflibercept for Persistent Central-Involved Diabetic Macular Edema
A Phase III Randomized Trial of Intravitreal Aflibercept Versus Intravitreal Bevacizumab + Deferred Aflibercept for Treatment of Central-Involved Diabetic Macular Edema
A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab every 4 weeks versus Aflibercept every 4 weeks in Adult Patients with Visual Impairment due to Diabetic Macular Edema
A phase III, multicenter, randomized, visual assessor-masked, active-comparator study of the efficacy, safety, and pharmacokinetics of the port delivery system with Ranibizumab in patients with Diabetic Macular Edema
Retinal Vein Occlusion
An Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion
An Eighteen-Month, Two-Arm, Randomized, Double-Masked, Multi-center, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Central Retinal Vein Occlusion
Telangiectasia
A Natural History Observation and Registry Study of Macular Telangiectasia Type 2 The MacTel Study
A Phase III, Multicenter, Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2
Uveitis
A Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye
An Open-label, Multi-center, Randomized, Phase II Study of the Safety, and Bioactivity of Two Dose Regimens of Subcutaneous Injections of ACTH Gel in Patients With Non-infectious Uveitis
Macular Edema Ranibizumab Vs. Intravitreal Anti-Inflammatory Therapy
A Phase III multicenter randomized, parallel-treatment, comparative effectiveness trial comparing adalimumab to conventional (small molecule) immunosuppression for corticosteroid spring in the treatment of non-infectious, intermediate, posterior, and panuveitides.
Nevus/Melanoma
Phase 1b Open-Label, single ascending dose clinical trial designed to evaluate the safety of two dose levels of light-activated AU-011-101 for the treatment of subject with small to medium (2.0mm-3.4mm thickness) primary choroidal melanoma
Identification of Germline BAP1 Mutation In Subjects With Choroidal Nevi or Uveal Melanoma
Radiation Retinopathy
The ARRT trial will assess the safety and efficacy of 2mg IAI for the treatment of radiation retinopathy, including maculopathy and optic neuropathy
